Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database
- PMID: 20810324
- DOI: 10.1016/j.jalz.2010.03.018
Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database
Abstract
Background: A mathematical model was developed to describe the longitudinal response in Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog) obtained from the Alzheimer's Disease Neuroimaging Initiative.
Methods: The model was fit to the longitudinal ADAS-cog scores from 817 patients. Risk factors (age, apolipoprotein ɛ4 [APOE ɛ4] genotype, gender, family history of AD, years of education) and baseline severity were tested as covariates.
Results: Rate of disease progression increased with baseline severity. Age, APOE ɛ4 genotype, and gender were identified as potential covariates influencing disease progression. The rate of disease progression in patients with mild to moderate AD was estimated as approximately 5.5 points/yr.
Conclusions: A disease progression model adequately described the natural decline of ADAS-cog observed in Alzheimer's Disease Neuroimaging Initiative. Baseline severity is an important covariate to predict a curvilinear rate of disease progression in normal elderly, mild cognitive impairment, and AD patients. Age, APOE ɛ4 genotype, and gender also influence the rate of disease progression.
Copyright © 2011 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Modeling Alzheimer's disease progression using the disease system analysis approach.Alzheimers Dement. 2012 Jan;8(1):39-50. doi: 10.1016/j.jalz.2010.12.012. Epub 2011 Jul 22. Alzheimers Dement. 2012. PMID: 21782528
-
Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease.Psychopharmacol Bull. 2001 Spring;35(2):83-96. Psychopharmacol Bull. 2001. PMID: 12397889
-
An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.J Clin Pharmacol. 2012 May;52(5):629-44. doi: 10.1177/0091270011405497. Epub 2011 Jun 9. J Clin Pharmacol. 2012. PMID: 21659625
-
Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?Int J Geriatr Psychiatry. 2009 Jun;24(6):638-47. doi: 10.1002/gps.2195. Int J Geriatr Psychiatry. 2009. PMID: 19123199
-
[Alzheimer disease].Nihon Rinsho. 2001 Dec;59 Suppl 8:504-10. Nihon Rinsho. 2001. PMID: 11808269 Review. Japanese. No abstract available.
Cited by
-
Calculating stage duration statistics in multistage diseases.PLoS One. 2011;6(12):e28298. doi: 10.1371/journal.pone.0028298. Epub 2011 Dec 7. PLoS One. 2011. PMID: 22163291 Free PMC article.
-
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.Lancet Neurol. 2013 Mar;12(3):233-43. doi: 10.1016/S1474-4422(13)70014-0. Epub 2013 Jan 31. Lancet Neurol. 2013. PMID: 23375965 Free PMC article. Clinical Trial.
-
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7. Alzheimers Dement. 2013. PMID: 23932184 Free PMC article. Review.
-
Testing whether the progression of Alzheimer's disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data.Alzheimers Res Ther. 2020 May 26;12(1):64. doi: 10.1186/s13195-020-00630-5. Alzheimers Res Ther. 2020. PMID: 32456710 Free PMC article.
-
Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes.Br J Clin Pharmacol. 2013 Jan;75(1):146-61. doi: 10.1111/j.1365-2125.2012.04308.x. Br J Clin Pharmacol. 2013. PMID: 22534009 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous